A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Histone deacetylase inhibitors (HDACi) have proven activity in hematologic malignancies, and their FDA approval in multiple myeloma (MM) and T-cell lymphoma highlights the need for further development of this drug class. We investigated AR-42, an oral pan-HDACi, in a first-in-man phase 1 dose escala...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Leuk Lymphoma
Autores principales: Sborov, Douglas W., Canella, Alessandro, Hade, Erinn M., Mo, Xiaokui, Khountham, Soun, Wang, Jiang, Ni, Wenjun, Poi, Ming, Coss, Christopher, Liu, Zhongfa, Phelps, Mitch A., Mortazavi, Amir, Andritsos, Leslie, Baiocchi, Robert A., Christian, Beth A, Benson, Don M., Flynn, Joseph, Porcu, Pierluigi, Byrd, John C., Pichiorri, Flavia, Hofmeister, Craig C.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5489371/
https://ncbi.nlm.nih.gov/pubmed/28270022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2017.1298751
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares